Circulating tumor cells: From bench to bedside

Annual Review of Medicine

Volumn 64, Issue , 2013, Pages 31-44

  Balic, Marija ^a   Williams, Anthony ^b   Lin, Henry ^c   Datar, Ram ^b   Cote, Richard J ^b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c Intelligent Optical Systems Inc   (United States)

Author keywords

cancer stem cells (CSCs); disseminated tumor cells (DTCs); micrometastasis; minimal residual disease; therapeutic response

Indexed keywords

CANCER INVASION; CANCER PATIENT; CANCER PROGNOSIS; CANCER STEM CELL; CELL SURVIVAL; CIRCULATING TUMOR CELL; DISSEMINATED CANCER; DRUG INDUSTRY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; METASTASIS; MOLECULAR BIOLOGY; PATIENT CARE; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

DIAGNOSIS, DIFFERENTIAL; EARLY DIAGNOSIS; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING;

EID: 84873028083     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-050311-163404     Document Type: Review

References (76)

1. Slamon DJ, Leyland-Jones B, Shak S, et al. 2001. Use of chemotherapy plus amonoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344:783-92
2. Baselga J, Cortes J, Kim SB, et al. 2012. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 366:109-19
3. Amado RG, Wolf M, Peeters M, et al. 2008. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26:1626-34
4. Redding WH, Monaghan P, Imrie SF. 1983. Detection ofmicrometastases in patients with primary breast cancer. Lancet 2:1271-74
5. Cote RJ, Rosen PP, Lesser ML, et al. 1991. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J. Clin. Oncol. 9:1749-56
6. Balic M. 2009. Disseminated tumor cells as biomarkers for breast cancer. Biomark. Med. 3:215-17
7. Braun S, Vogl FD, Naume B, et al. 2005. A pooled analysis of bone marrow micrometastasis in breast cancer. N. Engl. J. Med. 353:793-802
8. Giuliano AE, Hawes D, Ballman KV, et al. 2011. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA 306:385-93
9. Cristofanilli M, Budd GT, Ellis MJ, et al. 2004. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351:781-91
10. Bauernhofer T, Zenahlik S, Hofmann G, et al. 2005. Association of disease progression and poor overall survival with detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer. Oncol. Rep. 13:179-84
11. Miller MC, Doyle GV, Terstappen LW. 2010. Significance of circulating tumor cells detected by the CellSearch system in patients with metastatic breast colorectal and prostate cancer. J. Oncol. 2010:617421
12. Alix-Panabières C, Schwarzenbach H, Pantel K. 2012. Circulating tumor cells and circulating tumor DNA. Annu. Rev. Med. 63:199-215
13. Balic M, Lin H, Williams A, et al. 2012. Progress in circulating tumor cell capture and analysis: implications for cancer management. Expert Rev. Mol. Diagnostics 12:303-12
14. Cohen SJ, Punt CJ, Iannotti N, et al. 2008. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol. 26:3213-21
15. Cristofanilli M, Hayes DF, Budd GT, et al. 2005. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J. Clin. Oncol. 23:1420-30
16. Danila DC, HellerG, Gignac GA, et al. 2007. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin. Cancer Res. 13:7053-58
17. Iinuma H, Watanabe T, Mimori K, et al. 2011. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer. J. Clin. Oncol. 29:1547-55
18. Reinholz MM, Kitzmann KA, Tenner KS, et al. 2011. Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group (NCCTG) trials, N0234/336/436/437. Clin. Cancer Res. 17:7183-93
19. Nole F, Munzone E, Zorzino L, et al. 2008. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann. Oncol. 19:891-97
20. Balic M, Lin H, Williams A, et al. 2012. Progress in circulating tumor cell (CTC) capture and analysis: implications for cancer management. Expert Rev. Mol. Diagn. 12:303-12
21. Hayes DF, Cristofanilli M, Budd GT, et al. 2006. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin. Cancer Res. 12:4218-24
22. Riethdorf S, Fritsche H, Muller V, et al. 2007. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin. Cancer Res. 13:920-28
23. Scher HI, Jia X, de Bono JS, et al. 2009. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol. 10:233-39
24. de Bono JS, Scher HI, Montgomery RB, et al. 2008. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 14:6302-9
25. Gaforio JJ, Serrano MJ, Sanchez-Rovira P, et al. 2003. Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen-receptor status and predicts for poor prognosis. Int. J. Cancer 107:984-90
26. Ignatiadis M, KallergiG, Ntoulia M, et al. 2008. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin. Cancer Res. 14:2593-600
27. Xenidis N, Ignatiadis M, Apostolaki S, et al. 2009. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J. Clin. Oncol. 27:2177-84
28. Giuliano M, Giordano A, Jackson S, et al. 2011. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res. 13:R67
29. Rutgers E, Piccart-GebhartMJ, Bogaerts J, et al. 2011. The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase. Eur. J. Cancer 47:2742-49
30. Zujewski JA, Kamin L. 2008. Trial assessing individualized options for treatment for breast cancer: the TAILORx trial. Future Oncol. 4:603-10
31. Riethdorf S, Muller V, Zhang L, et al. 2010. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin. Cancer Res. 16:2634-45
32. Jäger B, Rack B, Schindlbeck C, et al. 2012. Survival in early breast cancer is influenced by circulating tumor cells-results from the SUCCESS A study. Presented at Eur. Breast Cancer Conf., 8th, Vienna, Mar. 21-24. Abstr. 301
33. Bidard FC, Hajage D, Bachelot T, et al. 2012. Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study. Breast Cancer Res. 14:R29
34. Hayes DF. 2012. A clinicians' perspective on metastasic breast cancer: many diseases-we need to understand the biology. Presented at Eur. Breast Cancer Conf., Vienna, 8th, Mar. 21-24
35. Budd GT, Cristofanilli M, Ellis MJ, et al. 2006. Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin. Cancer Res. 12:6403-9
36. Scheel C, Weinberg RA. 2011. Phenotypic plasticity and epithelial-mesenchymal transitions in cancer and normal stem cells? Int. J. Cancer 129:2310-14
37. Lee JM, Dedhar S, Kalluri R, et al. 2006. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J. Cell Biol. 172:973-81
38. Aktas B, Tewes M, Fehm T, et al. 2009. Stem cell and epithelial- mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res. 11:R46
39. Kallergi G, Papadaki MA, Politaki E, et al. 2011. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer 13:R59
40. Friedl P, Wolf K. 2003. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat. Rev. Cancer 3:362-74
41. Hou JM, Krebs MG, Lancashire L, et al. 2012. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J. Clin. Oncol. 30:525-32
42. Scheel C, Eaton EN, Li SH, et al. 2011. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 145:926-40
43. Talmadge JE, Donkor M, Scholar E. 2007. Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev. 26:373-400
44. Younos I, Donkor M, Hoke T, et al. 2011. Tumor- and organ-dependent infiltration by myeloid-derived suppressor cells. Int. Immunopharmacol. 11:816-26
45. Diaz-MonteroCM, SalemML, NishimuraMI, et al. 2009. Increased circulatingmyeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 58:49-59
46. Clevers H. 2011. The cancer stem cell: premises, promises and challenges. Nat. Med. 17:313-19
47. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. 2003. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 100:3983-88
48. Lawson JC, Blatch GL, Edkins AL. 2009. Cancer stem cells in breast cancer and metastasis. Breast Cancer Res. Treat. 118:241-54
49. Oliveira LR, Jeffrey SS, Ribeiro-Silva A. 2010. Stem cells in human breast cancer. Histol. Histopathol. 25:371-85
50. Huntly BJ, Gilliland DG. 2005. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat. Rev. 5:311-21
51. Singh SK, Hawkins C, Clarke ID, et al. 2004. Identification of human brain tumour initiating cells. Nature 432:396-401
52. Balic M, Lin H, Young L, et al. 2006. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin. Cancer Res. 12:5615-21
53. Buess M, Rajski M, Vogel-Durrer BM, et al. 2009. Tumor-endothelial interaction links the CD44+/CD24- phenotype with poor prognosis in early-stage breast cancer. Neoplasia 11:987-1002
54. Resetkova E, Reis-Filho JS, Jain RK, et al. 2009. Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res. Treat. 123:97-108
55. Charafe-Jauffret E, Ginestier C, Iovino F, et al. 2009. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 69:1302-13
56. Chute JP, Muramoto GG, Whitesides J, et al. 2006. Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proc. Natl. Acad. Sci. USA 103:11707-12
57. Ginestier C, Hur MH, Charafe-Jauffret E, et al. 2007. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1:555-67
58. Charafe-Jauffret E, GinestierC, Iovino F, et al. 2010. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin. Cancer Res. 16:45-55
59. Pantel K, Brakenhoff RH. 2004. Dissecting the metastatic cascade. Nat. Rev. Cancer 4:448-56
60. Schabel FM Jr. 1977. Rationale for adjuvant chemotherapy. Cancer 39:2875-82
61. PhillipsTM, McBrideWH, Pajonk F. 2006. The response of CD24-/low/CD44+ breast cancer-initiating cells to radiation. J. Natl. Cancer Inst. 98: 1777-85
62. Croker AK, Allan AL. 2012. Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44+ human breast cancer cells. Breast Cancer Res. Treat. 133:75-87
63. Ricardo S, Vieira AF, Gerhard R, et al. 2011. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J. Clin. Pathol. 64:937-46
64. Dearnaley DP, Ormerod MG, Sloane JP. 1991. Micrometastases in breast cancer: long-term follow-up of the first patient cohort. Eur. J. Cancer 27:236-39
65. Naume B, Wiedswang G, Borgen E, et al. 2004. The prognostic value of isolated tumor cells in bone marrow in breast cancer patients: evaluation of morphological categories and the number of clinically significant cells. Clin. Cancer Res. 10:3091-97
66. Abraham BK, Fritz P, McClellan M, et al. 2005. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin. Cancer Res. 11:1154-59
67. Wicha MS. 2006. Cancer stem cells and metastasis: lethal seeds. Clin. Cancer Res. 12:5606-7
68. Reuben JM, Lee BN, Gao H, et al. 2011. Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44CD24lo cancer stem cell phenotype. Eur. J. Cancer 47:1527-36
69. Theodoropoulos PA, Polioudaki H, Agelaki S, et al. 2010. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett. 288:99-106
70. Wang N, Shi L, Li H, et al. 2012. Detection of circulating tumor cells and tumor stem cells in patients with breast cancer by using flow cytometry: a valuable tool for diagnosis and prognosis evaluation. Tumour Biol. J. Int. Soc. Oncodev. Biol. Med. 33:561-69
71. Fehm T, Becker S, Duerr-Stoerzer S, et al. 2007. Determination ofHER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor wasHER2 negative or of unknown HER2 status. Breast Cancer Res. 9:R74
72. Munzone E, Nole F, Goldhirsch A, et al. 2010. Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer. Clin. Breast Cancer 10:392-97
73. SomloG, Lau SK, Frankel P, et al. 2011. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology. Breast Cancer Res. Treat. 128:155-63
74. Maheswaran S, Sequist LV, Nagrath S, et al. 2008. Detection of mutations in EGFR in circulating lungcancer cells. N. Engl. J. Med. 359:366-77
75. Dharmasiri U, Njoroge SK, Witek MA, et al. 2011. High-throughput selection, enumeration, electrokinetic manipulation, and molecular profiling of low-abundance circulating tumor cells using a microfluidic system. Anal. Chem. 83:2301-9
76. Yang MJ, Chiu HH, Wang HM, et al. 2010. Enhancing detection of circulating tumor cells with activating KRAS oncogene in patients with colorectal cancer by weighted chemiluminescent membrane array method. Ann. Surg. Oncol. 17:624-33